Research programme: azole antifungals - Essential Therapeutics/NAEJA
Alternative Names: Azole antifungals research programme - Essential Therapeutics/NAEJALatest Information Update: 18 Nov 2004
At a glance
- Originator Essential Therapeutics [CEASED]; NAEJA Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Aspergillosis; Candidiasis; Mycoses
Most Recent Events
- 18 Nov 2004 Discontinued - Preclinical for Aspergillosis in Canada (unspecified route)
- 18 Nov 2004 Discontinued - Preclinical for Aspergillosis in USA (unspecified route)
- 18 Nov 2004 Discontinued - Preclinical for Candidiasis in Canada (unspecified route)